Date
de révision : 16 avril 2010 |
 Bibliographie
Score MASCC
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al.
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Clin Oncol 2000;18(16):3038-51.
Neutropénie fébrile de faible risque
Freifeld A, Marchigiani D, Walsh T, Chanock S, Lewis L, Hiemenz J, et al.
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
N Engl J Med 1999;341(5):305-11.
Kern WV, Cometta A, De Bock R, Langenaeken J, Paesmans M, Gaya H.
Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
N Engl J Med 1999;341(5):312-8.
Malik IA, Abbas Z, Karim M.
Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
Lancet 1992;339(8801):1092-6.
Flaherty JP, Waitley D, Edlin B, George D, Arnow P, O'Keefe P, et al.
Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
Am J Med 1989;87(5A):278S-282S.
Giamarellou H, Bassaris HP, Petrikkos G, Busch W, Voulgarelis M, Antoniadou A, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
Antimicrob Agents Chemother 2000;44(12):3264-71.
Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, et al.
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
Cancer 1999;85(1):213-9.
Velasco E, Costa MA, Martins CA, Nucci M.
Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients.
Am J Clin Oncol 1995;18(5):429-35.
Turlure P, Durand-Zaleski I.
An organizational and economic approach in France to the ambulatory treatment of febrile neutropenia.
Presse Med 2004;33(5):338-42.
Retour à domicile précoce d'un patient en neutropénie fébrile
Innes HE, Smith DB, O'Reilly SM, Clark PI, Kelly V, Marshall E.
Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.
Br J Cancer 2003;89(1):43-9.
Kern WV.
Risk assessment and treatment of low-risk patients with febrile neutropenia.
Clin Infect Dis 2006;42(4):533-40.
Rubenstein EB, Rolston K.
Outpatient management of febrile episodes in neutropenic cancer patients.
Support Care Cancer 1994;2(6):369-73.
Innes H, Marshall E.
Outpatient therapy for febrile neutropenia.
Curr Opin Oncol 2007;19(4):294-8.
Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E.
Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Support Care Cancer 2008 May;16(5):485-91. Epub 2007 Sep 25.
Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, et al.
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Cancer 2005;103(12):2629-35.
Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, et al.
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
Support Care Cancer 2008.
Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, et al. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
J Clin Oncol 2006;24(25):4129-34.
Marqueurs (PCT et PCR) et neutropénie fébrile
Jimeno A, Garcia-Velasco A, del Val O, Gonzalez-Billalabeitia E, Hernando S, Hernandez R, et al.
Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia.
Cancer 2004;100(11):2462-9.
Massaro KS, Costa SF, Leone C, Chamone DA.
Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults.
BMC Infect Dis 2007;7:137.
Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, Anargyrou K, Katsilambros N, Giamarellou H.
Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia.
Clin Infect Dis 2001;32(12):1718-25.
Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R.
Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10.
Eur J Cancer Care (Engl) 2007 Nov ;16(6):475-83.
|
 |
